drugset / Trial / NCT05424445

MISOBEST - Orally Misoprostol Solution (Cytotec®) Versus Orally Misoprostol as a Tablet (Angusta®) for Induction of Labor

NCT05424445

Phase 3 Completed 884 enrolled Karolinska Institutet
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the study is to evaluate efficacy of the cervical ripening of misoprostol administration in oral tablet, Angusta® compared with the off-label solution of misoprostol (Cytotec®) for induction of labor (IOL). Since there is a large cost difference between the preparations (Angusta® is 43 times more expensive than Cytotec®) it is, from a socio-economic perspective, of great interest to evaluate if Angusta can be replaced by Cytotec.

Timeline

Start
2022-01-21
Primary completion
2022-12-31
Completion
2023-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Misoprostol Other / unclassified 25 ug Oral

Indications

No indication recorded.